Loading
The first bispecific ADC to extend both progression-free and overall survival in oesophageal cancer, for patients whose immunotherapy has stopped working.
Interim analysis met dual primary endpoints of OS and BICR-assessed PFS (announced February 2026; presented ASCO 2026). 249 vs 248 patients. Second-line ESCC previously had only single-agent chemotherapy (irinotecan, taxanes) with median OS under a year. Global confirmatory trials are being planned.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
497 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | Izalontamab brengitecan | - | 9.8 months | 0.64 (0.49 to 0.83) | 0.0004 | link |
| Chemotherapy (physician's choice) | - | 7.2 months | ||||
| Progression-free survival (BICR)primary | Izalontamab brengitecan | - | 4.2 months | 0.5 (0.4 to 0.63) | <0.0001 | link |
| Chemotherapy (physician's choice) | - | 2 months |
Shares Bispecific ADC, Izalontamab brengitecan.
Shares Bispecific ADC, Izalontamab brengitecan.
Shares Bispecific ADC, Izalontamab brengitecan.
Shares Bispecific ADC, Izalontamab brengitecan.
Shares Bispecific ADC, Izalontamab brengitecan.
Shares Bispecific ADC, Izalontamab brengitecan.
Shares Bispecific ADC, Izalontamab brengitecan.
Shares Bispecific ADC, Izalontamab brengitecan.